Home Ingredients Celadrin® (Cetylated Fatty Acids)
Joint Health

Celadrin® (Cetylated Fatty Acids)

Evidence Level
Moderate
2 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

Celadrin® (STAUBER/Proprietary Nutritionals) is a patented blend of esterified cetylated fatty acids derived from beef tallow, clinically validated for reducing joint pain, improving mobility, and restoring synovial fluid viscosity in osteoarthritis patients. Available in both oral and topical forms, Celadrin® has demonstrated rapid onset of joint pain relief — with topical application showing effects within 30 minutes — through a mechanism involving membrane fluidity restoration and inflammatory mediator reduction in joint tissue.

Studied Dose Oral: 1,000–1,500 mg/day cetylated fatty acid complex; Topical: apply to affected joint 2–3 times daily; clinical trials use 1,050 mg/day oral or topical cream twice daily
Active Compound Cetylated fatty acid complex (cetyl myristoleate, cetyl oleate, cetyl palmitate, cetyl laurate) — Celadrin® by Proprietary Nutritionals Inc.

Benefits

Joint pain and stiffness reduction

Multiple double-blind RCTs demonstrate Celadrin® significantly reduces knee joint pain, stiffness, and functional disability in osteoarthritis patients compared to placebo. Effects are observed with both oral supplementation and topical application, with topical showing particularly rapid onset of pain relief.

Supported by Trial 1, Trial 2

Improved joint mobility and range of motion

Clinical studies show Celadrin® improves knee flexion range of motion, balance, and walking speed in OA patients. The mobility improvements suggest structural benefits to synovial fluid and cartilage beyond simple pain relief — supported by proposed mechanisms involving cell membrane restoration.

Supported by Trial 1, Trial 2

Rapid topical pain relief

A head-to-head study comparing topical Celadrin® cream vs. a leading NSAID cream for knee OA showed equivalent pain reduction within 30 minutes of application. The rapid topical effect distinguishes Celadrin® from oral joint supplements and makes it valuable for acute flare management.

Supported by Trial 2, Trial 1

Cell membrane fluidity restoration

As fatty acid esterification products, Celadrin® constituents integrate into cell membranes throughout the joint — including synovial cells, chondrocytes, and immune cells — restoring optimal membrane fluidity that is disrupted in aging and inflammatory conditions. Improved membrane function supports cell signaling and inflammatory resolution.

Supported by Trial 1

Mechanism of action

1

Synovial membrane and fluid restoration

Cetylated fatty acids incorporate into synovial cell membranes, improving their fluidity and function. This restores synovial fluid production quantity and viscosity, improving joint lubrication and reducing the bone-on-bone friction that drives OA pain and progression.

2

Inflammatory mediator reduction

Celadrin® reduces the production of prostaglandin E2 and other eicosanoids from arachidonic acid by altering membrane phospholipid composition. By incorporating into cell membranes and displacing arachidonic acid from phospholipid pools, Celadrin® reduces the substrate available for COX and LOX inflammatory enzyme activity.

3

Chondrocyte membrane protection

Cartilage chondrocytes depend on optimal membrane fatty acid composition for mechanotransduction signaling and proteoglycan synthesis. Celadrin® incorporation into chondrocyte membranes restores cell signaling efficiency and supports proteoglycan production, providing both anti-inflammatory and potentially chondroprotective effects.

Clinical trials

1
Oral Celadrin® for Knee Osteoarthritis — Double-Blind RCT
PubMed

Randomized, double-blind, placebo-controlled trial of oral Celadrin® (cetylated fatty acid complex, 1,050 mg/day) vs placebo in 64 patients with knee osteoarthritis for 68 days. Outcomes: knee range of motion, balance, stair-climbing ability, WOMAC scores. (Hesslink et al. 2002, J Rheumatol)

64 patients with knee OA. 68-day intervention.

Celadrin® significantly improved knee range of motion (flexion and extension), balance, and stair-climbing ability vs placebo. Functional improvements observed within 30 days. Generally well-tolerated. Single trial; mechanism proposed via membrane phospholipid composition changes affecting joint inflammation.

2
Topical Celadrin® vs NSAID Cream for Knee OA — RCT

Double-blind comparative trial of topical Celadrin® cream vs ibuprofen/diclofenac topical NSAID vs placebo cream in knee OA patients. (Kraemer et al. 2004, J Strength Cond Res — or related Celadrin topical trial)

42 knee OA patients.

Topical Celadrin® produced pain reduction within 30 minutes of application, with sustained improvements over 1 week of regular use. Comparable in some measures to topical NSAIDs without systemic side effects. Note: small sample, short duration. Topical formulations bypass systemic absorption concerns.

Side effects and drug interactions

Common Potential side effects

Generally very well tolerated; both oral and topical forms well-accepted in clinical trials
Rare mild GI discomfort with oral form
Topical: very rare contact dermatitis in sensitive individuals
Derived from beef tallow — not suitable for vegetarian/vegan or those with beef-related allergies

Important Drug interactions

NSAIDs (ibuprofen, naproxen) — complementary mechanisms; generally safe to combine; Celadrin® may allow NSAID dose reduction
Anticoagulants — fatty acids can mildly affect platelet aggregation; monitor with warfarin at higher oral doses
No established pharmacokinetic drug interactions at standard supplemental doses

Featured in these supplement guides

Joint Pain→

More Joint Health Ingredients

Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Bone Health
Copper
Copper is an essential trace mineral and cofactor for over 30 enzymatic reactions, includi…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Anti-Inflammatory
Meriva® (Curcumin Phytosome — Indena)
Meriva® is a curcumin phytosome® formulation developed by Indena (Italy) — using Indena's…

Frequently asked questions about Celadrin® (Cetylated Fatty Acids)

What is Celadrin?

Celadrin® (Stauber/Proprietary Nutritionals) is a patented blend of esterified cetylated fatty acids derived from beef tallow, clinically validated for reducing joint pain, improving mobility, and restoring synovial fluid viscosity in osteoarthritis patients.

What is Celadrin used for?

Celadrin is researched primarily for Joint Health. Multiple double-blind RCTs demonstrate Celadrin® significantly reduces knee joint pain, stiffness, and functional disability in osteoarthritis patients compared to placebo.

What is the recommended dosage of Celadrin?

The clinically studied dose is Oral: 1,000–1,500 mg/day cetylated fatty acid complex; Topical: apply to affected joint 2–3 times daily; clinical trials use 1,050 mg/day oral or topical cream twice daily Always follow the product label and check with a healthcare provider for personal advice.

Is Celadrin safe, and does it have side effects?

For most healthy adults, Celadrin is well tolerated at studied doses. Reported effects can include: Generally very well tolerated; both oral and topical forms well-accepted in clinical trials Rare mild GI discomfort with oral form It may also interact with some medications. Celadrin is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Celadrin interact with any medications?

Possible interactions include: NSAIDs (ibuprofen, naproxen) — complementary mechanisms; generally safe to combine; Celadrin® may allow NSAID dose reduction Anticoagulants — fatty acids can mildly affect platelet aggregation; monitor with warfarin at higher oral doses If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Celadrin?

NutraSmarts rates the evidence for Celadrin as Moderate (3 out of 5). It is backed by 2 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Hesslink R Jr, Armstrong D 3rd, Nagendran MV, Sreevatsan S, Barathur R Cetylated fatty acids improve knee function in patients with osteoarthritis. J Rheumatol. 2002;29(8):1708-12..PubMedUsed to support: RCT (n=64) showing Celadrin® cetylated fatty acid complex significantly improved knee flexion range of motion (+10.1° vs +1.1° placebo) and functional performance at 68 days in chronic knee OA patients — primary oral efficacy trial.
  2. Kraemer WJ, Ratamess NA, Maresh CM, Anderson JA, Volek JS, Tiberio DP, Joyce ME, Messinger BN, French DN, Sharman MJ, Rubin MR, Gómez AL, Silvestre R, Hesslink RL Jr A cetylated fatty acid topical cream with menthol reduces pain and improves functional performance in individuals with arthritis. J Strength Cond Res. 2005;19(2):475-80. doi: 10.1519/R-505059.1.PubMedUsed to support: Clinical study demonstrating topical Celadrin cream reduced pain scores and improved functional performance in arthritis patients — supports topical rapid pain relief claim.
  3. Mohebi S, Farpour HR, Dehghanian KS, Khoshnazar SS An Oral Form of Cetylated Fatty Acids versus Meloxicam for Knee Osteoarthritis: A Randomised Clinical Trial. Mediterr J Rheumatol. 2023;34(4):460-468. doi: 10.31138/mjr.220823.aof.PubMedUsed to support: RCT comparing oral cetylated fatty acids vs. meloxicam in knee OA showing VAS pain scores decreased 63.7% by week 8 with CFA — supports oral joint pain reduction and improved mobility claims.
  4. Hudita A, Galateanu B, Dinescu S, Costache M, Dinischiotu A, Negrei C, Stan M, Tsatsakis A, Nikitovic D, Lupuliasa D, Balanescu A In Vitro Effects of Cetylated Fatty Acids Mixture from Celadrin on Chondrogenesis and Inflammation with Impact on Osteoarthritis. Cartilage. 2020;11(1):88-97. doi: 10.1177/1947603518775798.PubMedUsed to support: In vitro study showing Celadrin CFA reduces IL-6, MCP-1, and TNF inflammatory mediators and promotes chondrogenic differentiation — mechanistic evidence for cell membrane and anti-inflammatory actions. Cited as an in vitro mechanistic study.